Advanced search
Publication Cover
OncoImmunology Volume 4, 2015 - Issue 3
Submit an article Journal homepage
1,242
Views
7
CrossRef citations to date
0
Altmetric
Author's View

Tregs activated by bispecific antibodies

Killers or suppressors?

Stefanie KoristkaTumorimmunology; University Cancer Center (UCC); Medical Faculty Carl Gustav Carus; Technical University Dresden; Dresden, Germany
,
Marc CartellieriTumorimmunology; University Cancer Center (UCC); Medical Faculty Carl Gustav Carus; Technical University Dresden; Dresden, Germany;Cellex Patient Treatment GmbH; Dresden, Germany
,
Claudia ArndtTumorimmunology; University Cancer Center (UCC); Medical Faculty Carl Gustav Carus; Technical University Dresden; Dresden, Germany
,
Anja FeldmannHelmholtz-Zentrum Dresden-Rossendorf (HZDR); Institute of Radiopharmaceutical Cancer Research; Dresden, Germany
,
Barbara SeligerInstitute of Medical Immunology; Martin-Luther-University-Halle-Wittenberg; Halle, Germany
,
Gerhard EhningerMedical Clinic and Policlinic I; University Hospital ‘Carl Gustav Carus’; Dresden, Germany
&
Michael P. BachmannTumorimmunology; University Cancer Center (UCC); Medical Faculty Carl Gustav Carus; Technical University Dresden; Dresden, Germany;Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Institute of Radiopharmaceutical Cancer Research; Dresden, Germany;DFG-Center for Regenerative Therapies Dresden; Cluster of Excellence; Technical University Dresden; Dresden, GermanyCorrespondence[email protected]
 show all
Article: e994441 | Received 26 Nov 2014, Accepted 27 Nov 2014, Published online: 16 Mar 2015

References

  • Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I, Bartsch H, Bippes CC, Schmitz M, Cartellieri M, Bachmann M. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 2012; 1:172-98; PMID:NOT_FOUND; http://dx.doi.org/10.3390/antib1020172
  • Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, Michalk I, Töpfer K, Temme A, Kretschmer K, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188:1551-58; PMID:22184723; http://dx.doi.org/10.4049/jimmunol.1101760
  • Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
  • Koristka S, Cartellieri M, Arndt C, Feldmann A, Töpfer K, Michalk I, Temme A, Ehninger G, Bachmann M. Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity. Blood Cancer J 2014; 4:e199; PMID:24727995
  • Choi BD, Gedeon PC, Herndon JE 2nd, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res 2013; 1(3):163; PMID:24570975; http://dx.doi.org/10.1158/2326-6066.CIR-13-0049
  • Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology 2013; 2(12):e26757; PMID:AMBIGUOUS; http://dx.doi.org/10.4161/onci.26757
  • Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, Olek S, Dietmaier W, Andreesen R, Edinger M. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009; 39(4):1088-97; PMID:19283780; http://dx.doi.org/10.1002/eji.200838904
  • Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate 2011; 71(9):998-1011; PMID:21541976; http://dx.doi.org/10.1002/pros.21315
  • Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189(6):3249-59; PMID:22875801; http://dx.doi.org/10.4049/jimmunol.1200341
  • Efimova OV, Kelley TW. Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. BMC Immunol 2009; 10:59; PMID:19930596; http://dx.doi.org/10.1186/1471-2172-10-59

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.